UCB SA (OTCMKTS:UCBJY) Short Interest Down 90.0% in March

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 700 shares, a decline of 90.0% from the February 29th total of 7,000 shares. Based on an average daily volume of 14,300 shares, the short-interest ratio is currently 0.0 days.

UCB Stock Performance

UCBJY stock opened at $61.57 on Thursday. UCB has a 1-year low of $34.85 and a 1-year high of $62.53. The business has a 50-day moving average price of $53.13 and a 200 day moving average price of $45.06.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.